Novartis (NVS) to Release Earnings on Friday

Novartis (NYSE:NVS) is expected to be releasing its earnings data before the market opens on Friday, January 31st. Analysts expect Novartis to post earnings of $1.80 per share and revenue of $12,855,300.00 billion for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. The firm had revenue of $12.82 billion for the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period last year, the firm posted $1.74 earnings per share. On average, analysts expect Novartis to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Stock Performance

NYSE:NVS opened at $100.00 on Friday. The company’s 50-day moving average price is $100.22 and its 200-day moving average price is $108.81. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a market cap of $204.40 billion, a P/E ratio of 11.61, a P/E/G ratio of 1.44 and a beta of 0.57. Novartis has a twelve month low of $92.35 and a twelve month high of $120.92.

Wall Street Analysts Forecast Growth

NVS has been the subject of several recent analyst reports. BMO Capital Markets raised their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat.com, Novartis has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.